Large Phase 3 clinical trials have demonstrated the impressive benefits of SGLT-2 inhibitors on kidney and cardiovascular outcomes in CKD patients, irrespective of the presence or absence of T2D (Table 1) [11,12,13,14]. Here, SLC5A2 is linked to chronic kidney disease.